Advances in Critical Care for the Nephrologist: Acute Lung Injury/ARDS

Kathleen D. Liu and Michael A. Matthay
Departments of Medicine and Anesthesia, Cardiovascular Research Institute, University of California–San Francisco, San Francisco, California

Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are a major cause of acute respiratory failure in the critically ill patient. ALI and ARDS are characterized by the acute onset of severe hypoxemia and bilateral pulmonary infiltrates in the absence of clinical evidence for left atrial hypertension. These conditions are differentiated from one another by the ratio of the partial pressure of oxygen in the arterial blood to the inspired fraction of oxygen; ARDS requires a more severe oxygenation defect. ALI and ARDS may occur in association with a number of clinical disorders, including sepsis, pneumonia, aspiration, trauma including inhalational injury, and blood transfusions. The mortality rate remains high, in the range of 25% to 40%. The pathophysiology of ALI/ARDS involves resident lung cells, including endothelial and epithelial cells, as well as neutrophils, monocytes/macrophages, and platelets. When ALI/ARDS is complicated by acute kidney injury, mortality increases substantially. Several supportive and pharmacologic therapies have been tested in clinical trials. Of these, a low tidal volume, lung protective ventilation strategy is the only strategy that has been demonstrated in a large, multicenter randomized clinical trial to reduce mortality for patients with ALI/ARDS. Based on a recent randomized trial, a conservative fluid management strategy reduces the duration of mechanical ventilation without increasing the incidence of renal failure. Pharmacologic strategies and other ventilator management strategies have not been successful to date; however, several randomized, placebo controlled treatment trials are ongoing.

Published online ahead of print. Publication date available at www.cjasn.org.

Correspondence: Dr. Kathleen D. Liu, Division of Nephrology and Critical Care Medicine, Box 0532, University of California, San Francisco, San Francisco, CA 94143-0532. Phone: 415-476-2172; Fax: 415-476-3381; E-mail: Kathleen.Liu@ucsf.edu

Copyright © 2008 by the American Society of Nephrology

ISSN: 1555-9041/0001

CJASN ePress. Published on January 16, 2008 as doi: 10.2215/CJN.01630407
and move the field forward. However, we note that all disease definitions are at best, imperfect, and it seems more critical for the community to agree to adopt a single definition, rather than a perfect definition.

The main clinical challenges in differentiating ALI from cardiogenic pulmonary edema have been discussed in detail in a recent review article (8). The combination of history, physical examination, laboratory data, and the chest radiograph is usually sufficient to diagnose cardiogenic versus noncardiogenic pulmonary edema or ALI. In some patients, a transthoracic or transesophageal echocardiogram is required to make the distinction. Finally, there are some patients in whom pulmonary artery catheterization is required to determine both the etiology of the shock and the pathogenesis of the pulmonary edema.

**Epidemiology and Incidence**

Although considerable progress has been made in understanding the natural history and pathogenesis of ALI and ARDS, its incidence throughout the world remains uncertain. A recent population-based clinical study identified patients with ALI at all 18 hospitals in King County (9). The incidence of ALI in King County was 78.9 per 100,000 person-years and of ARDS was 58.7 cases per 100,000 person-years. Mortality was approximately 40%. By extrapolating the data in this study to the population of the United States, the estimated incidence of ALI is approximately 200,000 patients per year. Of note, the population of King County differs significantly from that of other regions in the United States; in general, the population is younger and more affluent, and it includes more Asians and fewer African Americans. This study also demonstrated that the incidence of and mortality from ALI/ARDS increases with age.

Lower incidence rates have been reported in Europe and Australia (10,11), although the reason for these lower incidence rates remains uncertain (12). These incidence rates have ranged from 18 to 34 cases per 100,000 patient-years for ALI. Nonetheless, the mortality rates reported in these studies were similar to the King County cohort. Differences in these populations may include differences in risk factors for ALI, including race and differing predisposition to conditions underlying ALI/ARDS, as well as differences in case ascertainment and health care delivery. The data on the incidence of ALI/ARDS in children are more limited. A recent prospective study identified 320 children with ALI at two pediatric hospitals in Northern California; the overall mortality rate was 22% (13). Thus, ALI is a major cause of morbidity and mortality in critically ill children and adults.

In addition, the incidence of multiple organ failure, particularly acute kidney injury, is also very common in patients with ALI/ARDS. In a recent analysis of data from the National Heart, Lung, and Blood Institute (NHLBI) ARDS Network factorial clinical trial of ketoconazole, lisofylline, and a low tidal volume ventilation strategy for ALI/ARDS, approximately 35% of subjects developed acute kidney injury over the first week of the study, defined as a rise in creatinine of 50% from baseline (K.D. Liu and M.A. Matthey, unpublished data). These subjects had a 59% mortality rate, compared with an overall mortality rate of 28% within the cohort. Similarly, multiple cohort studies have suggested that refractory hypoxemia is uncommonly the cause of death in patients with ALI/ARDS. Rather, sepsis or multisystem organ dysfunction is often the cause of death (14,15). Indeed, the major clinical predictors of mortality for patients with ALI/ARDS include age, sepsis, the number of associated nonrespiratory organ dysfunctions, other comorbidities, and treatment-associated factors (16,17). Interestingly, the degree of hypoxemia, as measured by the initial PaO2/FIO2, has not been shown to be an independent predictor of mortality in adults (18).

**Pathophysiology**

The pathophysiology of ALI/ARDS has been reviewed at length (1,2). The early phase of ALI is characterized by diffuse alveolar damage, with disruption of the alveolar epithelium and the presence of fibrin-rich hyaline membranes along the denuded basement membrane. Protein-rich pulmonary edema fluid can be found filling the alveolar spaces, along with neutrophils, macrophages, and erythrocytes. This protein-rich edema fluid accumulates because of increased capillary permeability, resulting in increased movement of fluid from the capillaries to the lung interstitium. Airspace filling is likely exacerbated by epithelial injury and a decrease in the capacity of the injured alveolar epithelium to reabsorb edema fluid (19). Whereas some patients appear to fully recover from ALI, a few patients go on to a later phase of ALI/ARDS characterized by persistent hypoxemia, as well as fibrosis and ongoing inflammation within the airspaces (20).

Multiple compartments of the lung, including the epithelium and endothelium, play critical roles in the pathogenesis of ALI/ARDS (reviewed in (1)). The alveolar epithelium shares many features with the tubular epithelium of the kidney, including the presence of highly polarized epithelial cells characterized by a free apical surface that faces the airspace in the case of the lung and the urinary space in the case of the kidney and a basal surface that is in contact with the basement membrane (Figure 1A). The apical surface is characterized by the presence of channels and transporters that drive ion and fluid reabsorption. In both cases, the epithelial cells are tightly joined to one another by a series of junctional complexes; these tight junctions are fluid-impermeable. The alveolar epithelium consists of type I cells, which comprise approximately 90% of the alveolar surface area, and type II cells, which have several critical functions, including surfactant protein production and vectorial ion transport. Type II cells are also thought to function as progenitor cells for type I cells after cellular injury. Injury to these cells results in the loss of the tight barrier of the epithelium as well as loss of polarity of these cells, which allows for the formation of pulmonary edema fluid and as well as a loss of the ability to efficiently reabsorb this fluid (21) (Figure 1B).

It is also clear that injury to the endothelial compartment plays a critical role in the pathogenesis of ALI/ARDS. Hemodynamic and ultrastructural studies first demonstrated that large and small vessels within the lung are damaged during ALI/ARDS, manifested as an increase in pulmonary vascular resistance during ALI/ARDS and by the presence of arterial
Figure 1. (A) Comparison of the alveolar and renal tubular epithelium. Left, cross section of an alveolus. The alveolar epithelium is composed of a mixture of type I and II cells. Water and ion channels are found on the apical and basolateral surfaces as shown. Right, cross section of the distal convoluted tubule. The renal tubular epithelium at this level is composed of principal cells and intercalated cells. ENaC, epithelial Na\(^+\) channel; CFTR, cystic fibrosis transmembrane conductance regulator; AQP, aquaporin. (B) Multiple pathogenic processes contribute to alveolar injury during acute lung injury/acute respiratory distress syndrome.
and capillary thrombi on autopsy (22). The pulmonary dead space fraction allows an estimation of the amount of obstruction and destruction within the pulmonary capillary bed. An elevated pulmonary dead space fraction correlates with mortality in mechanically ventilated patients with ALI/ARDS (23).

Several markers of dysregulated coagulation, including low levels of protein C and high levels of plasminogen activator inhibitor-1, are associated with increased mortality in patients with ALI/ARDS (24,25).

Increased capillary permeability has been demonstrated by the use of radiolabeled tracer compounds injected into the systemic circulation and comparing concentrations of these compounds in the pulmonary edema fluid and in plasma (26). Additional evidence of endothelial injury comes from studies demonstrating that endothelin-1 and von Willebrand factor levels are elevated in patients with ALI/ARDS (27–29). These proteins are released by endothelial cells following injury. Interestingly, higher levels of von Willebrand factor are associated with increased mortality in patients with ALI/ARDS (30).

Multiple cell types, including neutrophils, activated macrophages, and platelets, play critical roles in the pathogenesis of ALI/ARDS. Neutrophils appear to be retained in the lung following injury and release proteases, reactive oxygen and nitrogen species, inflammatory cytokines and growth factors. Platelets may play a role in enhancing lung endothelial injury in concert with neutrophils (31). Monocytes and macrophages release IL-1β and soluble TNF-α, which in turn stimulate local production of other cytokines, including the neutrophil chemoattractant factor IL-8. Endogenous inhibitors of these pro-inflammatory cytokines, including soluble TNF receptors IL-1 receptor antagonist and anti-inflammatory cytokines such as IL-10 are also up-regulated; the balance of pro-inflammatory and anti-inflammatory signals plays a critical role in disease pathogenesis (32). As will be discussed in more detail below, mechanical ventilation with excessive force results in direct lung injury, likely by causing direct capillary stress and through the release of pro-inflammatory cytokines.

It is also clear that there is significant cross-talk between the lung and other organs. Ischemia/reperfusion injury to the kidney results in increased pulmonary vascular permeability, as measured by Evans blue dye permeability (33). Furthermore, attenuation of renal injury with a pharmacologic agent such as α-melanocyte stimulating hormone reduces the degree of ALI (34). Similarly, in animal models, acid and ventilator-associated lung injury can result in acute kidney injury (35,36). The mechanisms by which each organ impacts the other remain unclear. In the case of the effect of ALI/ARDS on the kidney, mechanical ventilation may result in reduced renal perfusion, as well as lead to the expression of a number of inflammatory cytokines, including IL-6 and TNF-α, which may have deleterious consequences for other organs, including the kidney (37).

**Treatment**

Significant advances in the treatment of ALI have occurred in the past 10 years. To date, the major progress has occurred in identifying better supportive care treatment strategies, rather than identifying novel pharmacotherapies.

**Ventilator Treatment**

In the 1980s and early 1990s, several experimental and observational studies suggested that the traditional approach to ventilating patients with ALI might exacerbate lung injury (32). Clinical practice had been guided by the concept that a large tidal volume improved oxygenation in the injured lung (reviewed in (38)). Small, randomized clinical trials demonstrated conflicting results for a lower tidal volume strategy, with three studies not supporting a benefit and a single study suggesting that reduction of tidal volumes reduced barotrauma and had a positive impact on patient mortality (39–42). In the late 1990s, the NHLBI supported ARDS Network, a consortium of academic medical centers, carried out a large prospective, randomized clinical trial (n = 861) comparing a traditional ventilation strategy (12 ml/kg predicted body weight) to a lung protective ventilation strategy (6 ml/kg predicted body weight) (4). The lung protective strategy also required that the plateau airway pressure (which measures the pressure applied to small airways and the alveoli) be maintained at less than 30 cmH2O. The lung protective strategy allowed for permissive hypercapnia, that is, tidal volumes were reduced to as low as 4 ml/kg predicted body weight to achieve a plateau pressure of less than 30 cmH2O, provided arterial pH was greater than 7.15. The results showed a significant reduction in mortality from 40% to 31% with the use of the low tidal volume, pressure limited strategy (Table 1). The lung protective strategy was also associated with more ventilator free days and more ICU-free days. A follow-up randomized clinical trial by the ARDS Network demonstrated that the low tidal volume strategy was associated with a further reduction in mortality to 26%, an effect that was not altered by the use of high versus moderate levels of positive end expiratory pressure (43).

As further evidence of the benefit of this clinical strategy, several mechanistic studies have been published that demonstrated that the low tidal volume strategy is associated with a reduction in the release of inflammatory markers into the plasma of patients with lung injury. For example, patients treated with a low tidal volume strategy have a significant decrease in the pro-inflammatory cytokines IL-6 and IL-8 in the plasma (44). In addition, another study evaluated the release of biologic markers into the airspaces as well as the plasma of patients treated with a lung protective versus conventional ventilation strategy and also found that the severity of the acute inflammation was markedly reduced in the airspaces and plasma of patients treated with a lung protective strategy (45). It should be noted that whether the benefit of the low tidal volume ventilation strategy is attributable to the low tidal volume per se or to the maintenance of a plateau pressure of less than 30 mm H2O or both cannot be determined from the results of the ARDS Network trial; this issue is further discussed in (46).

Many have suggested that in the injured lung, recruitment of atelectatic alveoli (“the open lung concept”) could be important for optimization of respiratory parameters (47). Ventilator strategies designed to open alveoli and to prevent atelectrauma, that is, trauma occurring from repeated opening and closing of alveoli, include the use of higher levels of positive end-expira-
Blood.

THAM is cleared by the kidney and therefore needs to be used with caution in patients with acute or chronic impairments in glomerular filtration rate. More importantly, if the patient has acute or chronic kidney disease and a concomitant metabolic acidosis, early treatment of the metabolic acidosis with renal replacement therapy should be considered to prevent complications of severe, combined respiratory/metabolic acidosis, which may include arrhythmias and hemodynamic instability (55). With regards to modality of renal replacement therapy, hemofiltration may be preferable to dialysis in the patient with severe metabolic acidosis, as hemofiltration allows for delivery of more base equivalents (typically in the form of bicarbonate).

**Table 1. NHBLI ARDS Network Low Tidal Volume Treatment Protocol**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventilator mode</td>
<td>Volume assist-control</td>
</tr>
<tr>
<td>Tidal volume</td>
<td>( \leq 6 \text{ ml/kg ideal body weight} )</td>
</tr>
<tr>
<td>Plateau pressure</td>
<td>( \leq 30 \text{ cmH}_2\text{O} )</td>
</tr>
<tr>
<td>Set respiratory rate</td>
<td>6 to 35 breaths/min, adjusted to achieve arterial pH ( \geq 7.30 ) if possible</td>
</tr>
<tr>
<td>(on the ventilator)</td>
<td></td>
</tr>
<tr>
<td>Arterial pH</td>
<td>No set goal per se, but ventilator rate adjusted as above</td>
</tr>
<tr>
<td>Oxygenation goal</td>
<td>( \text{PaO}_2 \geq 55 \text{ mmHg or oxyhemoglobin saturation by pulse oximetry of 88% to 95%} )</td>
</tr>
<tr>
<td>Fio(_2/\text{PEEP}^b) (cmH(_2\text{O})) combinations</td>
<td>(0.3/5, 0.4/5, 0.4/8, 0.5/8, 0.5/10, 0.6/10, 0.7/10, 0.7/12, 0.7/14, 0.8/14, 0.9/14, 0.9/16, 0.9/18, 1.0/18, 1.0/20, 1.0/22, 1.0/24; ) further increases in PEEP allowed to 34 cmH(_2\text{O} ) allowed but not required</td>
</tr>
<tr>
<td>Inspiratory flow</td>
<td>Adjusted to achieve inspiratory time/expiration time of 1:1 to 1:3</td>
</tr>
<tr>
<td>Weaning</td>
<td>Attempts to wean to pressure support ventilation when Fio(_2/\text{PEEP}^c \leq 0.4/8 )</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Variable</th>
<th>Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventilator mode</td>
<td>Volume assist-control</td>
</tr>
<tr>
<td>Tidal volume</td>
<td>( \leq 6 \text{ ml/kg ideal body weight} )</td>
</tr>
<tr>
<td>Plateau pressure</td>
<td>( \leq 30 \text{ cmH}_2\text{O} )</td>
</tr>
<tr>
<td>Set respiratory rate</td>
<td>6 to 35 breaths/min, adjusted to achieve arterial pH ( \geq 7.30 ) if possible</td>
</tr>
<tr>
<td>(on the ventilator)</td>
<td></td>
</tr>
<tr>
<td>Arterial pH</td>
<td>No set goal per se, but ventilator rate adjusted as above</td>
</tr>
<tr>
<td>Oxygenation goal</td>
<td>( \text{PaO}_2 \geq 55 \text{ mmHg or oxyhemoglobin saturation by pulse oximetry of 88% to 95%} )</td>
</tr>
<tr>
<td>Fio(_2/\text{PEEP}^b) (cmH(_2\text{O})) combinations</td>
<td>(0.3/5, 0.4/5, 0.4/8, 0.5/8, 0.5/10, 0.6/10, 0.7/10, 0.7/12, 0.7/14, 0.8/14, 0.9/14, 0.9/16, 0.9/18, 1.0/18, 1.0/20, 1.0/22, 1.0/24; ) further increases in PEEP allowed to 34 cmH(_2\text{O} ) allowed but not required</td>
</tr>
<tr>
<td>Inspiratory flow</td>
<td>Adjusted to achieve inspiratory time/expiration time of 1:1 to 1:3</td>
</tr>
<tr>
<td>Weaning</td>
<td>Attempts to wean to pressure support ventilation when Fio(_2/\text{PEEP}^c \leq 0.4/8 )</td>
</tr>
</tbody>
</table>

\(^a\)Adapted from reference 59, with permission.

\(^b\)Fio\(_2\), fraction of inspired oxygen; PEEP, positive end expiratory pressure; PaO\(_2\), partial pressure of oxygen in arterial blood.

Ventilator Management: Implications for Nephrologists

The landmark clinical trial by the ARDS Network has resulted in a major change in clinical practice, with a general recognition that patients with ALI should be ventilated with lower tidal volumes and a plateau pressure limit, even if there is significant hypercapnia. Thus, patients with ALI/ARDS will often have a mild respiratory acidosis, which is generally well tolerated. Indeed, it has been proposed that hypercapnic acidosis may have an independent protective effect on the lung (50–52). The respiratory acidosis associated with the low tidal volume lung protective ventilation strategy does not require treatment, although clinicians are often reluctant to maintain an arterial pH less than 7.25. Of note, if acute treatment is provided in the form of bicarbonate, the bicarbonate will be converted to CO\(_2\) and may exacerbate the respiratory acidosis, especially when bicarbonate is administered rapidly or in bolus form (53). An alternative therapy is THAM (tromethamine; tris-hydroxymethyl aminomethane), a chemically inert base (54). However, THAM is cleared by the kidney and therefore needs to be used with caution in patients with acute or chronic impairments in glomerular filtration rate. More importantly, if the patient has acute or chronic kidney disease and a concomitant metabolic acidosis, early treatment of the metabolic acidosis with renal replacement therapy should be considered to prevent complications of severe, combined respiratory/metabolic acidosis, which may include arrhythmias and hemodynamic instability (55). With regards to modality of renal replacement therapy, hemofiltration may be preferable to dialysis in the patient with severe metabolic acidosis, as hemofiltration allows for delivery of more base equivalents (typically in the form of bicarbonate).

**Fluid Management**

Another advance in supportive therapy was recently reported by the NHLBI ARDS Network with a prospective, randomized clinical trial that evaluated the use of a liberal versus conservative fluid strategy in patients with ALI (Figure 2) (5). The results demonstrated that a fluid conservative strategy resulted in a significant increase in ventilator-free days and a nonsignificant decrease in mortality by 3%. The conservative fluid management strategy used diuretics to target a central venous pressure less than 4 mmHg or a pulmonary artery occlusion pressure less than 8 mmHg. This treatment strategy resulted in essentially even fluid balance over the first 7 d of the study. Subjects in the fluid liberal arm achieved approximately the same fluid balance as subjects enrolled in previous ARDS Network clinical trials (56). Patients were not treated with diuretic therapy if they had hypotension in the previous 12 h on the study protocol.

In the same clinical trial, the investigators also evaluated the value of central venous pressure monitoring versus pulmonary artery pressure monitoring (57). The results showed that there was no benefit of use the pulmonary artery catheter in implementation of the two fluid strategies, thus suggesting that, for most patients with ALI, central venous monitoring is adequate; this result supports the results of several other randomized clinical trials and observational studies. Nevertheless, there are some patients with refractory shock or difficult-to-diagnose pulmonary edema in
whom pulmonary artery catheterization still has important value, both for diagnosis and management (8).

**Fluid Management: Implications for Nephrologists**

Although worsening renal function was a theoretical concern in the fluid management trial, there was no significant difference in the need for dialysis between those treated with the fluid liberal and fluid conservative strategies (14% versus 10%, \( P = 0.06 \)). Indeed, fewer patients in the fluid conservative arm were treated with dialysis than in the fluid liberal arm. Of note, the primary reason for initiating dialysis was not recorded, so individuals in the two trial arms may have had different indications for dialysis (for example, volume overload/hypoxemia in the fluid liberal group and azotemia in the fluid conservative group). However, the role of dialysis in fluid management in patients with ALI/ARDS remains uncertain; patients with dialysis-requiring acute kidney injury at the time of study eligibility were excluded from enrollment in the FACTT trial. While the fluid conservative strategy did not result in an additional need for dialysis, the potential impact of the fluid conservative strategy on already established acute kidney injury (especially with regards to renal recovery) remains uncertain. Furthermore, the optimal timing of the initiation of dialysis in the critical care setting remains uncertain.

**Pharmacologic Treatments**

Numerous clinical trials have evaluated pharmacologic therapies for the treatment of ALI (reviewed in (56,58,59)). Unfortunately, no pharmacologic treatment has yet been shown to reduce mortality. These include several phase II and phase III clinical trials of intravenous glucocorticoids to reduce inflammation in both acute and late phase ARDS. Glucocorticoids have not been shown to be of benefit in either acute phase or late phase ARDS. In a recently completed phase III trial, the ARDS Network demonstrated no mortality benefit to glucocorticoid administration in patients with ARDS for more than 7 d and in fact increased mortality in those treated with glucocorticoids more than 14 d after the onset of ARDS (60). Steroid administration was not associated with an increased risk of infection but with an increase in neuromyopathy. The use of glucocorticoids for relative adrenal insufficiency in the intensive care unit has recently become more controversial (61,62). It should be noted that steroids in general may increase protein catabolism and azotemia in patients with acute kidney injury, so an understanding of the evidence-based indications for steroid administration in the critical care setting is crucial for nephrologists.

Other pharmacologic therapies for ALI/ARDS have included inhaled nitric oxide, which provides selective pulmonary vaso-dilation and increases ventilation perfusion matching. However, studies to date have not shown mortality benefit to inhaled nitric oxide; it can be considered as a rescue therapy in patients with severe, refractory hypoxemia. Exogenous surfactant has not been shown to have benefits in adults with ALI/ARDS, although a recent study has suggested that surfactant may benefit children with ALI/ARDS (63). The Pediatric Acute Lung Injury and Sepsis Interventional group is planning on repeating this study in a larger number of pediatric patients. Antifungal agents (ketoconazole) and phosphodiesterase inhibitors (lisofoylline) have been studied in several clinical trials, including negative studies from the ARDS Network. It has been shown in isolated human lung models, animal studies, as well as a small, single-center randomized clinical trial of 40 subjects that \( \beta \)-agonists may accelerate the clearance of extravascular lung water (64,65). It has also been demonstrated in healthy volunteers that \( \beta \)-agonists may reduce inflammation (66). Based on these observations, the ARDS Network is starting a multicenter, randomized clinical trial of inhaled \( \beta \)-agonists for the treatment of ALI and ARDS.

**Conclusion**

Acute lung injury and the ARDS are major causes of acute respiratory failure in the critically ill adult. Similar to acute kidney injury, the pathogenesis of these conditions is complex and involves multiple cell compartments, including the highly differentiated alveolar epithelium, endothelium as well as inflammatory cells, including neutrophils and macrophages. Although multiple pharmacologic therapies have been tried, the only interventions to
date that have reduced the mortality of this condition have been supportive care strategies (ventilator management). These advances have been greatly facilitated by a National Institutes of Health Clinical Trials Network whose primary mission is to reduce the morbidity and mortality of patients with ALI and the ARDS as well as by the widespread adoption of a consensus definition for ALI/ARDS that has allowed for more uniform comparison of subjects across studies. While progress has been made toward a consensus definition for acute kidney injury, ultimately, patients with acute kidney injury would benefit from a similar network to carry out clinical trials focused on individuals with early acute kidney injury.

Disclosures

None.

References


57. Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D,


